Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Laromustine + Daunorubicin + Cytarabine in AML
NCT00840684Phase 2Completed
- Sponsor
- Institut Paoli-Calmettes
- Start
- Jan 2009
- Primary completion
- May 2011
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of laromustine in acute myeloid leukemia (AML), sponsored by Institut Paoli-Calmettes. Started Jan 2009; status: completed.
02
Drugs
laromustine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00840684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00840684.